New shares of Revenio Group Corporation registered with the trade register

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

As previously announced, Revenio Group Corporation (“Revenio” or the “Company”) has completed its rights offering (the “Offering”) where the Company offered for subscription, based on the pre-emptive rights for existing shareholders, a maximum of 12,929,361 new shares in the Company (the “Offer Shares”). Revenio announced the final result of the Offering on October 15, 2026.

A total of 12,929,361 Offer Shares have been registered in the trade register maintained by the Finnish Patent and Registration Office (the “Trade Register”) today, October 16, 2026. Following the registration of the Offer Shares, the total number of issued shares in the Company is 42,096,274.

The Offer Shares will entitle their holders to dividend and other distribution of funds, if any, and to other shareholder rights in the Company after the Offer Shares have been recorded in the Company’s shareholders’ register maintained by Euroclear Nordics Oy on or about October 19, 2026. Trading with the Offer Shares is expected to commence on the regulated market of Nasdaq Helsinki Ltd on or about October 19, 2026.

For further information, please contact
CEO Jouni Toijala
+358 50 484 0085
jouni.toijala@revenio.fi

Distribution
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Main media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a leading turnkey solutions provider in the global eye care market. The group offers fast, user-friendly, and reliable tools for diagnosing a wide variety of eye diseases. Revenio’s solutions include e.g. tonometers, fundus imaging devices, optical coherence tomography (OCT), perimeters, multimodal devices, refraction systems, and software solutions under iCare and Visionix. 

In May 2026, Revenio joined forces with Visionix, creating the most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology. In 2025, the Group’s net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. In 2025, the Group’s pro forma net sales totaled EUR 252.8 million, with a pro forma adjusted EBITDA of EUR 45.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V. 

Important Information

This announcement is not being made in and copies of it may not be distributed or sent into the United States, the United Kingdom, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa.

This announcement is not a prospectus for the purposes of the Prospectus Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and underlying legislation. The prospectus prepared pursuant to the Prospectus Regulation (the “Prospectus”) has been published and can be obtained from the Company and other places indicated in the Prospectus. Investors should not subscribe for or purchase any securities referred to in this announcement except on the basis of information contained in the Prospectus.

This announcement does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The Company does not intend to register any of the securities in the United States or to conduct a public offering of the securities in the United States.

In any member state of the European Economic Area other than Finland (each a “Relevant State”), this information and this offering are only addressed to and directed at (a) persons who are “Qualified Investors” within the meaning of Article 2(e) of the Prospectus Regulation; or (b) in any other circumstances falls within Article 1(4) of the Prospectus Regulation. The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, such investors. This announcement should not be acted upon or relied upon in any Relevant State by persons who do not fulfill such criteria.

This announcement does not constitute an offer of the securities to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the securities. This announcement is being distributed to and is directed only at (i) persons who are outside the United Kingdom, (ii) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (iii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). Any investment activity to which this announcement relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.

This announcement contains unaudited pro forma financial information, which are presented for the year ended December 31, 2025, for illustrative purposes only to give effect to the Visionix Transaction and its financing to the Company’s historical financial information. The unaudited pro forma financial information may differ from the Company’s actual financial results. The unaudited pro forma financial information does not purport to project any future financial results of the Company.

The global coordinator is acting exclusively for the Company and no one else in connection with the Offering. The global coordinator will not regard any other person (whether or not a recipient of this announcement) as its client in relation to the Offering. The global coordinator will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the Offering or any transaction or arrangement referred to in this announcement.

Forward-looking Statements

This announcement includes “forward-looking statements.” These statements may not be based on historical facts, but are statements about future expectations. When used in this release, the words “aims,” “anticipates,” “assumes,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “should,” “will,” “would” and similar expressions as they relate to the Company and the transaction identify certain of these forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. These forward-looking statements are based on present plans, estimates, projections and expectations and are not guarantees of future performance. They are based on certain expectations, which, even though they seem to be reasonable at present, may turn out to be incorrect. Such forward-looking statements are based on assumptions and are subject to various risks and uncertainties. Readers should not rely on these forward-looking statements. Numerous factors may cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied in the forward-looking statements. Neither the Company nor any of its affiliates, advisors, representatives or any other person undertakes any obligation to review, confirm or publicly release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise following the date of this announcement.